2A3單克隆抗體與三硝基苯酚反應(yīng)。由于哺乳動(dòng)物不表達(dá)三硝基苯酚，這種抗體非常適合在大多數(shù)體內(nèi)和體外應(yīng)用中用作大鼠IgG2a抗體的同種型匹配對(duì)照。

艾美捷InVivoMAb大鼠IgG2a同種型對(duì)照，抗三硝基苯酚：

貨號(hào)：BXC-BE0089

亞型：大鼠IgG2a，κ

由LAL凝膠凝固測(cè)定法確定

推薦稀釋液：InVivoPure pH 6.5稀釋液

偶聯(lián)：未偶聯(lián)。提供抗體偶聯(lián)服務(wù)。

配方：PBS，pH 6.5

不含穩(wěn)定劑或防腐劑

內(nèi)毒素：<2EU/毫克（<0.002EU/微克）

由LAL凝膠凝固測(cè)定法確定

純度：>95%

由SDS-PAGE確定

無(wú)菌性：0.2微米過(guò)濾

在無(wú)動(dòng)物設(shè)施中從細(xì)胞培養(yǎng)上清液中純化

純化：蛋白質(zhì)G

分子量：150 kDa

儲(chǔ)存：抗體溶液應(yīng)以原始濃度在4°C下儲(chǔ)存。不要冷凍。

InVivoMAb大鼠IgG2a同種型對(duì)照文獻(xiàn)參考：

Bauche, D., et al. (2018). "LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis" Immunity 49(2): 342-352 e345.

Ngiow, S. F., et al. (2015). "A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1" Cancer Res 75(18): 3800-3811.

Dai, M., et al. (2015). "Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies" Clin Cancer Res 21(5): 1127-1138.

Kurtulus, S., et al. (2015). "TIGIT predominantly regulates the immune response via regulatory T cells" J Clin Invest. doi : 10.1172/JCI81187.

Ellis, G. T., et al. (2015). "TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection" EMBO Rep 16(9): 1203-1218.

Walsh, K. B., et al. (2014). "Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy" J Virol 88(11): 6281-6293.